Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance

Heart

Volumn 99, Issue 20, 2013, Pages 1476-1480

  Camm, A John ^a   Savelieva, Irene ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DIGOXIN; DOFETILIDE; DRONEDARONE; PLACEBO;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84884590344     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-3013-303863     Document Type: Review

References (35)

1. European Medicines Agency. Assessment report for Multaq. 2009. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Public- assessment-report/human/001043/WC500044538. pdf (accessed).
2. Camm AJ, Camm CF, Savelieva I. Medical treatment of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012;13:97-107.
3. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24:1481-7.
4. Singh BN, Connolly SJ, Crijns HJ, et al. EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99.
5. Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527.e1-9.
6. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605.
7. Køber L, Torp-Pedersen C, McMurray JJ, et al. Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
8. Hohnloser SH, Crijns HJ, van Eickels M, et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
9. Erratum in: N Engl J Med 2009;360:2487
10. N Engl J Med 2011;364:1481.
11. Connolly SJ, Camm AJ, Halperin JL, et al.; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
12. Savelieva I, Kirchhof P, Danchin N, et al. Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. Europace 2011;13:1063-76.
13. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
14. Møller M, Torp-Pedersen CT, Køber L. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congest Heart Fail 2001;7:146-50.
15. Torp-Pedersen C, Moller M, Kober L, et al. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure. Eur Heart J 2000;21:1204-6.
16. Hohnloser SH, Crijns HJ, van Eickels M, et al.; ATHENA Investigators. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010;31:1717-21.
17. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174-80.
18. Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329-45.
19. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012;5:CD005049.
20. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-95.
21. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2009/022425lbl.pdf (accessed).
22. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG. Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
23. NICE. Atrial fibrillation - dronedarone: final appraisal determination. 2010. http://guidance.nice.org.uk/TA/ Wave19/57/FAD/FinalAppraisalDetermination/ pdf/ English (accessed).
24. Joghetaei N, Weirich G, Huber W, et al. Acute liver failure associated with dronedarone. Circ Arrhythm Electrophysiol 2011;4:592-3.
25. US FDA. Drug Safety Communication. http://www. fda.gov/drugs/drugsafety/ ucm240011.htm (accessed).
26. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/ human/001043/WC500044534.pdf (accessed).
27. Siu CW, Wong MP, Ho CM, et al. Fatal lung toxic effects related to dronedarone use. Arch Intern Med 2012;172:516-17.
28. Hernández Voth AR, Catalán JS, Benavides Mañas PD, et al. A 73-year-old man with interstitial lung disease due to dronedarone. Am J Respir Crit Care Med 2012;186:201-2.
29. Nieuwlaat R, Hohnloser SH, Connolly SJ. Effect of dronedarone in patients with permanent atrial fibrillation during the ATHENA study. Eur Heart J 2011;32(Suppl.):618.
30. Skanes AC, Healey JS, Cairns JA, et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/ rhythm control. Can J Cardiol 2012;28:125-36.
31. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/ AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in partnership with the European Society f Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101-98.
32. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
33. US FDA. Multaq (dronedarone hydrochloride) tablets. 2012. http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ucm243762.htm (accessed).
34. Camm AJ, Arden C, Choy AM, et al. Translating regulatory advice into practice: use of dronedarone and older antiarrhythmics in AF management. Br J Cardiol 2012;19:e2-8.
35. NICE. Dronedarone for the treatment of nonpermanent atrial fibrillation. 2012. http://www.nice. org.uk/nicemedia/live/13115/50469/50469.pdf (accessed).